Ionis' antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021PRNewsWire • 11/12/21
Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meetingPRNewsWire • 11/07/21
Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/03/21
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/03/21
Ionis reports third quarter 2021 financial results and recent business achievementsPRNewsWire • 11/03/21
Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemiaPRNewsWire • 11/02/21
Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/27/21
Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALSPRNewsWire • 10/17/21
Ionis Pharmaceuticals (IONS) Up 3% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/03/21
Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meetingPRNewsWire • 09/03/21
Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/04/21
Ionis reports second quarter 2021 financial results and recent business achievementsPRNewsWire • 08/04/21
Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular eventsPRNewsWire • 08/02/21
Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAICPRNewsWire • 07/26/21